We have a number of product candidates that are in preclinical development, including a novel prodrug of methylhydrogenfumarate (MHF), known as XP23829, that we believe may provide higher blood levels of MHF and exhibit less gastric irritation than dimethylfumarate (DMF), another prodrug of MHF. Prodrugs of MHF, a molecule that appears to have anti-inflammatory properties, may be useful in the potential treatments of patients with MS or psoriasis. We have also developed a novel prodrug of acamprosate that appears to be more readily absorbed after oral administration than the current formulation of acamprosate. In November 2010, we were awarded a grant through the Michael J. Fox Foundation for Parkinson’s Research to support a preclinical study of the efficacy and safety of our acamprosate prodrug in reducing L-Dopa-induced dyskinesias in a preclinical model of Parkinson’s disease. We plan to continue our development of XP23829, our acamprosate prodrug and other preclinical assets, such as XP21510, a potential treatment for bleeding disorders, as resources permit.